Pasithea Therapeutics Corp Stock Performance
| KTTAW Stock | USD 0.02 0 8.97% |
Pasithea Therapeutics holds a performance score of 14 on a scale of zero to a hundred. The company holds a Beta of -3.58, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Pasithea Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Pasithea Therapeutics is expected to outperform it. Use Pasithea Therapeutics downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on Pasithea Therapeutics.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Pasithea Therapeutics Corp are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Pasithea Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of tradable shares by Pd Joint Holdings, Llc Series 2016-a of Pasithea Therapeutics subject to Rule 16b-3 | 06/13/2024 |
2 | Pasithea Therapeutics Corp. announced that it expects to receive 5.000003 million in funding - Marketscreener.com | 09/25/2024 |
3 | Acquisition by Dumesnil Simon of 10000 shares of Pasithea Therapeutics at 1.07 subject to Rule 16b-3 | 11/26/2024 |
| Begin Period Cash Flow | 33.1 M |
Pasithea |
Pasithea Therapeutics Relative Risk vs. Return Landscape
If you would invest 1.13 in Pasithea Therapeutics Corp on September 3, 2024 and sell it today you would earn a total of 0.90 from holding Pasithea Therapeutics Corp or generate 79.65% return on investment over 90 days. Pasithea Therapeutics Corp is currently producing 5.548% returns and takes up 30.0015% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Pasithea, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Pasithea Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pasithea Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pasithea Therapeutics Corp, and traders can use it to determine the average amount a Pasithea Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1849
| Best Portfolio | Best Equity | KTTAW | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 30.0 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Pasithea Therapeutics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pasithea Therapeutics by adding it to a well-diversified portfolio.
Pasithea Therapeutics Fundamentals Growth
Pasithea Stock prices reflect investors' perceptions of the future prospects and financial health of Pasithea Therapeutics, and Pasithea Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pasithea Stock performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.38 | ||||
| Revenue | 486.56 K | ||||
| EBITDA | (15.33 M) | ||||
| Net Income | (15.51 M) | ||||
| Cash And Equivalents | 568.98 K | ||||
| Cash Per Share | 0.07 X | ||||
| Total Debt | 81.68 K | ||||
| Current Ratio | 37.55 X | ||||
| Book Value Per Share | 22.46 X | ||||
| Cash Flow From Operations | (13.43 K) | ||||
| Total Asset | 26.12 M | ||||
| Retained Earnings | (35.32 M) | ||||
| Working Capital | 14.06 M | ||||
About Pasithea Therapeutics Performance
Evaluating Pasithea Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pasithea Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pasithea Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.90) | |
| Return On Capital Employed | (0.68) | (0.71) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.68) | (0.65) |
Things to note about Pasithea Therapeutics performance evaluation
Checking the ongoing alerts about Pasithea Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pasithea Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pasithea Therapeutics is way too risky over 90 days horizon | |
| Pasithea Therapeutics has some characteristics of a very speculative penny stock | |
| Pasithea Therapeutics appears to be risky and price may revert if volatility continues | |
| Pasithea Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 486.56 K. Net Loss for the year was (15.51 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pasithea Therapeutics Corp has accumulated about 568.98 K in cash with (13.43 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Pasithea Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pasithea Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pasithea Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pasithea Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pasithea Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pasithea Therapeutics' stock. These opinions can provide insight into Pasithea Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.